Reviva Pharmaceuticals Holdings, Inc. (RVPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
RVPH Stock Price Chart Interactive Chart >
RVPH Price/Volume Stats
|Current price||$1.71||52-week high||$5.69|
|Prev. close||$1.73||52-week low||$1.34|
|Day high||$1.79||Avg. volume||403,347|
|50-day MA||$1.98||Dividend yield||N/A|
|200-day MA||$2.83||Market Cap||25.88M|
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Company Bio
Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.
Most Popular Stories View All
RVPH Latest News Stream
|Loading, please wait...|
RVPH Latest Social Stream
View Full RVPH Social Stream
Latest RVPH News From Around the Web
Below are the latest news stories about Reviva Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate RVPH as an investment opportunity.
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - CUPERTINO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory di
Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!
By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT FDA ‘Study May Proceed’ Letter Received Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced on January 10, 2022 the receipt of a May Proceed letter from the FDA regarding pivotal Phase III clinical trials for brilaroxazine in schizophrenia, including one long-term safety trial. Through the letter, the FDA allowed
Welcome back, trader!
Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia
- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications - - Initiation of both Phase 3 trials is expected by end of January 2022 - CUPERTINO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of
RVPH Price Returns